Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges
The long and short noncoding RNAs have been involved in the molecular diagnosis, targeted therapy, and predicting prognosis of lung cancer. Utilizing noncoding RNAs as biomarkers and systemic RNA interference as an innovative therapeutic strategy has an immense likelihood to generate novel concepts...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-04-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317697578 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850092812816613376 |
|---|---|
| author | Haihua Tian Chengwei Zhou Jie Yang Jingqiu Li Zhaohui Gong |
| author_facet | Haihua Tian Chengwei Zhou Jie Yang Jingqiu Li Zhaohui Gong |
| author_sort | Haihua Tian |
| collection | DOAJ |
| description | The long and short noncoding RNAs have been involved in the molecular diagnosis, targeted therapy, and predicting prognosis of lung cancer. Utilizing noncoding RNAs as biomarkers and systemic RNA interference as an innovative therapeutic strategy has an immense likelihood to generate novel concepts in precision oncology. Targeting of RNA interference payloads such as small interfering RNAs, microRNA mimetic, or anti-microRNA (antagomirs) into specific cell types has achieved initial success. The clinical trials of noncoding RNA–based therapies are on the way with some positive results. Many attempts are done for developing novel noncoding RNA delivery strategies that could overcome systemic or local barriers. Furthermore, it precipitates concerted efforts to define the molecular subtypes of lung cancer, characterize the genomic landscape of lung cancer subtypes, identify novel therapeutic targets, and reveal mechanisms of sensitivity and resistance to targeted therapies. These efforts contribute a visible effect now in lung cancer precision medicine: patients receive molecular testing to determine whether their tumor harbors an actionable come resistance to the first-generation drugs are in clinical trials, and drugs targeting the immune system are showing activity in patients. This extraordinary promise is tempered by the sobering fact that even the newest treatments for metastatic disease are rarely curative and are effective only in a small fraction of all patients. Thus, ongoing and future efforts to find new vulnerabilities of lung cancers unravel the complexity of drug resistance, increase the efficacy of immunotherapies, and perform biomarker-driven clinical trials are necessary to improve the outcome of lung cancer patients. |
| format | Article |
| id | doaj-art-1c93e14264cb4e399b1d271dd019d1d0 |
| institution | DOAJ |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-1c93e14264cb4e399b1d271dd019d1d02025-08-20T02:42:02ZengSAGE PublishingTumor Biology1423-03802017-04-013910.1177/1010428317697578Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challengesHaihua Tian0Chengwei Zhou1Jie Yang2Jingqiu Li3Zhaohui Gong4Department of Laboratory Medicine, Ningbo Kangning Hospital, Ningbo, ChinaDepartment of Thoracic Surgery, The Affiliated Hospital of Ningbo University School of Medicine, Ningbo, ChinaZhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, ChinaZhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, ChinaZhejiang Provincial Key Laboratory of Pathophysiology, Ningbo University School of Medicine, Ningbo, ChinaThe long and short noncoding RNAs have been involved in the molecular diagnosis, targeted therapy, and predicting prognosis of lung cancer. Utilizing noncoding RNAs as biomarkers and systemic RNA interference as an innovative therapeutic strategy has an immense likelihood to generate novel concepts in precision oncology. Targeting of RNA interference payloads such as small interfering RNAs, microRNA mimetic, or anti-microRNA (antagomirs) into specific cell types has achieved initial success. The clinical trials of noncoding RNA–based therapies are on the way with some positive results. Many attempts are done for developing novel noncoding RNA delivery strategies that could overcome systemic or local barriers. Furthermore, it precipitates concerted efforts to define the molecular subtypes of lung cancer, characterize the genomic landscape of lung cancer subtypes, identify novel therapeutic targets, and reveal mechanisms of sensitivity and resistance to targeted therapies. These efforts contribute a visible effect now in lung cancer precision medicine: patients receive molecular testing to determine whether their tumor harbors an actionable come resistance to the first-generation drugs are in clinical trials, and drugs targeting the immune system are showing activity in patients. This extraordinary promise is tempered by the sobering fact that even the newest treatments for metastatic disease are rarely curative and are effective only in a small fraction of all patients. Thus, ongoing and future efforts to find new vulnerabilities of lung cancers unravel the complexity of drug resistance, increase the efficacy of immunotherapies, and perform biomarker-driven clinical trials are necessary to improve the outcome of lung cancer patients.https://doi.org/10.1177/1010428317697578 |
| spellingShingle | Haihua Tian Chengwei Zhou Jie Yang Jingqiu Li Zhaohui Gong Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges Tumor Biology |
| title | Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges |
| title_full | Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges |
| title_fullStr | Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges |
| title_full_unstemmed | Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges |
| title_short | Long and short noncoding RNAs in lung cancer precision medicine: Opportunities and challenges |
| title_sort | long and short noncoding rnas in lung cancer precision medicine opportunities and challenges |
| url | https://doi.org/10.1177/1010428317697578 |
| work_keys_str_mv | AT haihuatian longandshortnoncodingrnasinlungcancerprecisionmedicineopportunitiesandchallenges AT chengweizhou longandshortnoncodingrnasinlungcancerprecisionmedicineopportunitiesandchallenges AT jieyang longandshortnoncodingrnasinlungcancerprecisionmedicineopportunitiesandchallenges AT jingqiuli longandshortnoncodingrnasinlungcancerprecisionmedicineopportunitiesandchallenges AT zhaohuigong longandshortnoncodingrnasinlungcancerprecisionmedicineopportunitiesandchallenges |